The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial
Open accessAbstract
Objective: To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis. Methods: A total of 943 patients with primary progressive multiple sclerosis were randomized to GA or placebo (PBO) in this 3‐year, double‐blind trial. The primary end point was an intention‐to‐treat analysis of time to 1‐ (entry expanded disability status scale, 3.0–5.0) or 0.5‐point expanded disability status scale change (entry expanded disability status scale, 5.5–6.5) sustained for 3 months. The trial was stopped after an interim analysis by an independent data safety monitoring board indicated no discernible treatment effect on the primary outcome. Intention‐to‐treat analyses of disability and magnetic resonance imaging end points were performed. Results: There was a nonsignificant delay in time to sustained accumulated disability in GA‐ versus PBO‐treated patients (hazard ratio, 0.87 [95% confidence interval, 0.71–1.07]; p = 0.1753), with significant decreases in enhancing lesions in year 1 and smaller increases in T2 lesion volumes in years 2 and 3 versus PBO. Post hoc analysis showed that survival curves for GA‐treated male patients diverged early from PBO‐treated male subjects (hazard ratio, 0.71 [95% confidence interval, 0.53–0.95]; p = 0.0193). Interpretation: The trial failed to demonstrate a treatment effect of GA on primary progressive multiple sclerosis. Both the unanticipated low event rate and premature discontinuation of study medication decreased the power to detect a treatment effect. Post hoc analysis suggests GA may have slowed clinical progression in male patients who showed more rapid progression when untreated. Ann Neurol 2007;61:14–24
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.1.133 · Cited by 1,452
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,309
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P. A., Koopman, W. J., Hader, W., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,163
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Self-citationComi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group (2001) · Annals of Neurology · doi:10.1002/ana.64 · Cited by 650
Self-citationPrognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
Runmarker, B., & Andersen, O. (1993) · Brain · doi:10.1093/brain/116.1.117 · Cited by 568
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1998) · Neurology · doi:10.1212/wnl.50.3.701 · Cited by 509
Self-citationInterferon β-1a in primary progressive MS: An exploratory, randomized, controlled trial
Leary, S. M., Miller, D. H., Stevenson, V. L., Brex, P. A., Chard, D. T., & Thompson, A. J. (2003) · Neurology · doi:10.1212/wnl.60.1.44 · Cited by 251
Rovaris, M. (2001) · Brain · doi:10.1093/brain/124.12.2540 · Cited by 174
Bornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Drexler, E., Keilson, M., Spada, V., Weiss, W., Appel, S., Rolak, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.533 · Cited by 173
Self-citationLinomide in relapsing and secondary progressive MS: Part II: MRI results
Wolinsky, J. S., Narayana, P. A., Noseworthy, J. H., LUBLIN, F. D., Whitaker, J. N., Linde, A., Gjörstrup, P., & Sullivan, H. C. (2000) · Neurology · doi:10.1212/wnl.54.9.1734 · Cited by 143
Self-citationKalkers, N. F., Barkhof, F., Bergers, E., van Schijndel, R. A., & Polman, C. H. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms849xx · Cited by 136
Wolinsky, J. S., Narayana, P. A., & Johnson, K. P. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700107 · Cited by 109
Self-citationThe natural history of primary progressive MS in British Columbia, Canada
Tremlett, H. L., Paty, D. W., & Devonshire, V. A. (2005) · Neurology · doi:10.1212/01.wnl.0000188880.17038.1d · Cited by 102
Natural history of primary progressive multiple sclerosis
Ebers, G. C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1025oa · Cited by 93
The diagnosis of primary progressive multiple sclerosis
Wolinsky, J. S. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00346-5 · Cited by 76
Self-citationThompson, A. J. (2004) · Multiple Sclerosis Journal · doi:10.1177/135245850401000102 · Cited by 66
A dual approach for minimizing false lesion classifications on magnetic resonance images
Bedell, B. J., Narayana, P. A., & Wolinsky, J. S. (1997) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910370114 · Cited by 62
Self-citationOverview of European pilot study of interferon b-1b in primary progressive multiple sclerosis
Montalbán, X. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1033oa · Cited by 57
Magnetic resonance spectroscopy in multiple sclerosis: window into the diseased brain
Wolinsky, J. S., & Narayana, P. A. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00004 · Cited by 51
Self-citationPrimary progressive multiple sclerosis: increasing clarity but many unanswered questions
McDonnell, G. V., & Hawkins, S. A. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00053-9 · Cited by 45
Cited by
Compston, A., & Coles, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61620-7 · Cited by 4,372
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Self-citationHawker, K., O'Connor, P., Freedman, M. S., Calabresi, P. A., Antel, J., Simon, J., Hauser, S., Waubant, E., Vollmer, T., Panitch, H., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 934
Self-citation
Metadata
- Authors
- Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., & PROMiSe Trial Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2007-01
- Volume
- 61
- Issue
- 1
- Pages
- 14-24
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2046941822
- Cited by
- 429
- References
- 24
- FWCI
- 16.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.